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Abstract
Polychemotherapeutic protocols for the treatment of pediatric acute lymphoblastic leukemia (ALL) always include 
thiopurines. Specific approaches vary in terms of drugs, dosages and combinations. Such therapeutic schemes, including 
risk-adapted intensity, have been extremely successful for children with ALL who have reached an outstanding 5-year 
survival of greater than 90% in developed countries. Innovative drugs such as the proteasome inhibitor bortezomib and 
the bi-specific T cell engager blinatumomab are available to further improve therapeutic outcomes. Nevertheless, daily 
oral thiopurines remain the backbone maintenance or continuation therapy. Pharmacogenetics allows the personalization 
of thiopurine therapy in pediatric ALL and clinical guidelines to tailor therapy on the basis of genetic variants in TPMT  
and NUDT15  genes are already available. Other genes of interest, such as ITPA  and PACSIN2 , have been implicated in 
interindividual variability in thiopurines efficacy and adverse effects and need additional research to be implemented 
in clinical protocols. In this review we will discuss current literature and clinical guidelines available to implement 
pharmacogenetics for tailoring therapy with thiopurines in pediatric ALL.
Keywords: Thiopurines, acute lymphoblastic leukemia, therapy personalization, thiopurine methyltransferase, NUDT15 , 
PACSIN2 , inosine triphosphate pyrophosphatase, pharmacogenetics clinical implementation
INTRODUCTION
Thiopurines such as mercaptopurine and thioguanine (MP and TG, Figure 1A and B respectively) are 
lympholytic drugs used in all phases of therapy for acute lymphoblastic leukemia (ALL), with MP being part 
of the mainstay maintenance therapy[1]; instead, the MP prodrug azathioprine (AZA, Figure 1C) is employed 
in non-malignant conditions such as inflammatory bowel disease (IBD), including Crohn’s disease (CD) and 
ulcerative colitis (UC) during the maintenance phase of treatment[2].
Thiopurines are antimetabolites similar in structure to purines: in particular MP is an analogue of 
hypoxanthine and TG of guanine. In cells, thiopurines undergo complex anabolic and catabolic processes. The 
anabolic pathway produces thionucleotides (TGN), including thioguanosine mono-, di-, tri-phosphate (tGMP, 
tGDP, tGTP) and deoxythioguanosine mono-, di-, tri-phosphate (tdGMP, tdGDP, tdGTP), associated with 
therapeutic efficacy. The conversion of MP to tdGMP/tGMP involves the consecutive action of the enzymes 
of salvage pathway of nucleotides biosynthesis, in particular hypoxanthine phosphoribosyltransferase 1 
(HPRT1), inositol monophosphate dehydrogenase (IMPDH) and guanosine monophosphate synthetase 
(GMPS), whereas TG is directly converted by HPRT1 in a single step reaction [Figure 2]. The resulting tdGTP/
tGTP thionucleotides antagonize the incorporation of canonical dGTP and GTP into DNA and RNA, thus 
impairing DNA and RNA polymerases and subsequently inducing cell-cycle arrest and apoptosis because 
of altered DNA, RNA and protein synthesis[3]. Furthermore, the cytotoxic action of these drugs in lymphoid 
cells is implemented by additional mechanisms of action such as the inhibition of the purine de novo synthesis 
pathway and tGTP-mediated inhibition of Ras-related C3 botulinum toxin substrate 1 (Rac-1), a GTPase of 
the Rho family[3]. Catabolic pathways of thiopurines are mediated by the enzymes xanthine oxidase (XO) 
and thiopurine methyltransferase (TPMT). The extensive first-pass metabolism of the drug by XO in the 
liver and intestinal mucosa is responsible for the low bioavailability of oral MP (less than 20%) and generates 
the main inactive metabolite, 6-thiouric acid, excreted in the urine[4]. Indeed, it is known that allopurinol, a 
structural isomer of hypoxanthine and a XO inhibitor, influences thiopurine pharmacokinetics and promotes 
TGN production[4]. MP and TG are also converted into methylmercaptopurine (MMP) derivatives by TPMT. 
This reaction can occur also in cells different from hepatocytes, since TPMT is ubiquitously expressed. 
MMP is not converted to nucleotides, as it is a poor HPRT substrate and has no antileukemic activity[5]. The 
synthesis of MMP therefore is in competition with the anabolic pathway of thiopurines. TPMT catalyses 
the S-methylation also of intermediate thionucleotides leading to TGN, producing secondary methylated 
nucleotides (MMPN), with potential cytotoxic activity through the inhibition of de novo purine synthesis. The 
balance between TGN and MMPN has been related to thiopurines response and cytotoxicity[6]. In IBD, TGN 
concentrations between 230 and 450 pmol/8 × 108 red blood cells (RBC) are associated with the therapeutic 
index and clinical efficacy, while higher TGN concentrations have been related to myelosuppression and 
other severe complications such as infections[7]; concentrations of MMPN above 5,700 pmol/8 × 108 RBC have 
been associated with hepatotoxicity[8]. To authors’ knowledge, there is no general consensus for the range 
of TGN/MMPN plasma concentrations that should be achieved for drug efficacy and toxicity in ALL: some 
clinical protocols suggest MP dose reduction with TGN concentration above 1000 pmol/8 × 108 RBC in order 
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Figure 1. Thiopurines chemical structure. A: thioguanine; B: mercaptopurine; C: azathioprine
A B C
to avoid excessive toxicity[9]. Thiopurine active metabolites persist in the blood for a long time in contrast to 
MP plasma concentration that rapidly declines after oral administration (MP serum peak is achieved within 
2 h, half-life ranges from 20 to 120 min according to patients age and drug formulation): TGN are detected 
in RBC by the 3rd day of treatment and reach the steady state around the 3rd week; in IBD patients, clinical 
response to thiopurines is further delayed and appears between weeks 8 and 17 of therapy making these 
drugs unsuitable to achieve early disease remission but useful in long-term maintenance treatments[10]. TGN 
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Figure 2. Thiopurine pathway. MP: mercaptopurine; MMP: methyl-mercaptopurine; TIMP: thioinosine monophosphate; Me-TIMP: 
methyl-thioinosine monophosphate; TGDP: thioguanine diphosphate; TGMP: thioguanine monophosphate; TGTP: thioguanine 
triphosphate; TITP: thioinosinetriphosphate; Me-TITP: methylthioinosinetriphosphate; TGN: thioguanine nucleotide; TU acid: thiouric 
acid; TXMP: thioxantine monophosphate; AZA: azathioprine; IMPDH: Inosine-5′-monophosphate dehydrogenase; ITPA: inosine 
triphosphate pyrophosphatase; GMPS: GMP synthase; GST: glutathione-transferase; NUDT15: nucleotide triphosphate diphosphatase 
gene; PACSIN2: Protein kinase C and casein kinase substrate in neurons protein 2; TPMT: thiopurine methyltransferase; XO: xanthine 
oxidase. Hatched arrow indicates the infleunce of PACSIN2  on TPMT  gene expression and TPMT activity
are routinely detected in RBC rather than in leukocytes, although RBC lack IMPDH and have therefore a 
thiopurine metabolism different from with that of principal target cells of these drugs. However, erythrocyte 
TGN levels have been found to correlate to leukocyte TGN levels in pediatric patients[11,12].
In ALL, thiopurines are always used in the context of a polychemotherapeutic protocol that comprises 
glucocorticoids, vincristine, asparaginase, cytarabine, anthracyclines, cyclophosphamide and tyrosine-
kinase inhibitors such as imatinib; in particular, MP is used in combination with methotrexate[13-15]. Specific 
ALL polychemotherapeutic approaches differ across worldwide protocols in terms of drugs, dosages and 
combinations; however, they consistently share the therapeutic scheme with an initial remission-induction 
phase to eradicate the burden of tumoral cells and restore normal hematopoiesis, followed by a remission-
consolidation therapy and then by a long-term maintenance regimen (up to 24 months after diagnosis) to 
eliminate minimal residual leukemic cells. Such therapeutic scheme, combined with a risk-adapted intensive 
polychemotherapy, has been extremely successful for children with ALL who have reached an outstanding 
5-year survival greater than 90% in developed countries. Two of the currently running main clinical trials in 
childhood ALL, the European AIEOP-BFM (Associazione Italiana di Ematologia ed Oncologia Pediatrica-
Berlin-Frankfurt-Munster) 2017 protocol and the Total Therapy XVII (TOTAL XVII) used at the St. Jude 
Children’s Research Hospital (SJCRH) in Memphis, USA (ClinicalTrials.gov identifiers: NCT03643276 and 
NCT03117751, respectively http://clinicaltrials.gov) are aimed at further improving cure rate and quality 
of life of patients by exploring the effect of innovative drugs such as the proteasome inhibitor bortezomib 
and the bi-specific T cell engager blinatumomab. Nevertheless, thiopurines continue to be of interest: 
indeed, being administered daily throughout the duration of the entire therapy, although introduced 4/5 
weeks after diagnosis and therapy start (i.e., after the induction phase), they remain the backbone of the 
polychemotherapy in both clinical trials. A detailed assessment of thiopurine metabolism and, in particular, 
of MP tolerance, toxicity and treatment outcome is one of the explorative objectives of the SJCRH TOTAL 
XVII protocol. 
The most common drug related adverse effect of thiopurines is bone marrow suppression: leukopenia is a 
well-recognized effect occurring in more than 50% of ALL patients and 15%-20% in IBD patients[16], leading 
to dose reductions or therapy interruption, with consequent increase of disease recurrence and infection 
rate. Gastrointestinal complication are also very common in terms of anorexia, diarrhea, nausea, vomiting 
and stomatitis; the use of thiopurines may be limited also by the development of pancreatitis, although 
this complication is very rare in ALL patients (< 5%)[17]. Among other drug related adverse effects, there are 
hepatic toxicity and flu-like symptoms.
PHARMACOGENETICS 
Pharmacogenetics of thiopurines in pediatric ALL is very well studied. Table 1 summarizes the genetic 
factors involved in thiopurine toxicities and further discussed in this review: TPMT variants have the major 
established role in clinics; clinical guidelines are now also available for NUDT15 polymorphisms, whereas 
the pharmacogenetic contributions of other mentioned genes are either smaller or not yet steadily confirmed 
and therefore require further studies for their clinical implementation. 
TPMT
TPMT (EC 2.1.1.67) is ~30 kDa cytosolic enzyme expressed ubiquitously in cells. Its function on xenobiotics 
is very well established: as already mentioned above, it is responsible for the formation of methylated 
thiopurines derivatives and its activity is inversely related to the cytoplasmic accumulation of TGN[18]. In 
contrast, the endogenous function of TPMT is unknown: however, a role in the methylation of endogenous 
selenoproteins has been hypothesized and a very recent study confirmed in vitro a role for TPMT in the 
biosynthesis of selenocysteine[19]. Additionally, also a role in the biosynthesis of the molibdenum-binding 
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co-factor molybdopterin has been postulated but not fully demonstrated yet[20]. TPMT is encoded by a 27 
kb gene, composed of 10 exons, located in the short arm of chromosome 6[21]. Its expression varies and the 
patient genetic background is responsible for the observed interindividual differences in clinical efficacy 
and hematologic toxicity of thiopurine therapy[22]. Recent genome-wide association studies (GWAS) have 
provided evidences of TPMT as the only monogenic trait that influences the TPMT phenotype, finding that 
only variants in TPMT gene are significantly associated with TPMT activity in ALL children at genome-
wide level (n = 1,026; P = 8.6 × 10-61) and in a mixed-population (two cohorts of adult healthy volunteers 
and one of pediatric ALL patients, n = 1,212; P = 1.2 × 10-72)[23,24]. TPMT activity is inherited as an autosomal 
codominant trait and approximately 1 in 300 individuals has very low TPMT activity, 10% have intermediate 
activity and 89% show normal/high activity[25]. Indeed 10% of Europeans are positive for a genetic variant in 
TPMT and 0.5% are TPMT completely defective[26]. Studies that correlate TPMT genotype and phenotype in 
different populations show that there are more than 38 allelic variants responsible for a possible impairment 
of the enzyme activity[27]. However, only few alleles, such as TPMT*2 and TPMT*3, comprise 95% of the loss 
of function variants and therefore are clinically relevant. TPMT*2 allele (Single Nucleotide Polymorphism 
(SNP) rs1800462) is defined by the 238G>C transversion and the p.Ala80Pro amino acid substitution, 
whereas the TPMT*3 family alleles are defined by the SNPs 460G>A (rs1800460, p.Ala154Thr) and 719A>G 
(rs1142345, p.Tyr240Cys). In particular, TPMT*3A is the haplotype characterized by both 460G>A and 
719A>G transitions, TPMT*3B corresponds to the SNP rs1800460 alone and TPMT*3C to the single SNP 
rs1142345[27]. Genetic variants affecting TPMT activity are different among the main ethnic groups: indeed, 
the TPMT*3A is the variant most present in Europeans, while TPMT*3C is the most frequent in African 
and South-east Asian populations (allele frequency of 3%)[28]. In Africans, an additional allele putatively 
presenting reduced enzymatic activity, TPMT*8, identified by the polymorphism rs56161402, is present[29]. 
All these genetic variations lead to TPMT activity alterations: several studies have shown that the mechanism 
for decreased levels of TPMT protein and catalytic activity is the enhanced degradation of TPMT allozymes 
Table 1. Putative pharmacogenetic indicator for thiopurines
Gene Protein function Genetic variants Influence on mercaptopurine response in patients Ref.
TPMT S-methylation* rs1800462 
(*2, 238C>G, pAla80Pro)
rs1800460 
(*3B, 460G>A, p.Ala154Thr)
rs1142345 
(*3C, 719A>G, p.Tyr240Cys)
Severe leukopenia and 
hematological toxicity in 
carriers of the variant alleles
[36]
NUDT15
 
Diphosphatase, catalyses 
the hydrolysis of nucleoside 
triphosphates and their oxidized 
forms 
rs116855232 
(415C>T, p.Arg139Cys)
rs147390019 
(416G>A, p.Arg139His)
rs186364861 
(52G>A, p.Val18Ile)
rs746071566 
(Insertion 36_37insGGAGTC p.Val18_
Val19insGlyVal)
Thiopurine intolerance 
and adverse drug reaction 
in carriers of the loss-of-
function NUDT15 genetic 
polymorphisms
[41]
[42]
[43]
[36]
PACSIN2 Vesicle formation, endocytosis 
and caveole biogenesis
rs2413739 (T>C) Severe gastrointestinal and 
haematological toxicities in TT 
genotype patients
[70]
[71]
ITPA Pyrophosphatase that hydrolyzes 
the non-canonical purine 
nucleotides inosine triphosphate 
rs1127354 (94C>A, p.Pro32Thr)
rs7270101 (IV2 +21A>C)
Severe febrile neutropenia and 
hepatotoxicity in carriers of 
the variant alleles
[59]
[6]
*A natural substrate for this enzyme has yet to be identified. ITPA: Inosine triphosphate pyrophosphatase; NUDT15: nucleotide 
triphosphate diphosphatase; PACSIN2: Protein kinase C and casein kinase substrate in neurons protein 2 TPMT: Thiopurine 
S-methyltransferase
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encoded by the TPMT*2 and TPMT*3A alleles[30-32]. These TPMT activity alterations are related to a high risk 
of severe side effects during thiopurine treatment. Many studies have demonstrated that standard thiopurine 
doses administration is correlated to a higher risk of developing severe and even fatal hematologic toxicity 
in individuals with low TPMT activity compared to individuals without genetic variations in this gene. In 
particular, this side effect is due to the accumulation of TGN[33]. Murine models knock-out for Tpmt do not 
show any apparent phenotype in the absence of drug challenge, whereas they present differences in TGN 
concentrations, MMPN concentrations and toxicity among Tpmt(-/-), Tpmt(+/-), and Tpmt(+/+) genotypes 
when thiopurines are administered, resembling the same phenotype of human individuals carrying TPMT 
defective polymorphisms[34].
Clinical guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC) are currently 
available and recommend to assess TPMT status in term of either genetic variations or activity in ALL 
and IBD patients before starting thiopurine therapy, in order to optimize dosages and thus drug efficacy 
and tolerance[35,36]. Nonetheless, there are many cases of patients without TPMT defective variants who 
are intolerant to a full dose of thiopurines and present leukopenia or other adverse effects, suggesting that 
also other genes or environmental factors can contribute to the risk of these side effects during thiopurine 
therapy[37].
NUDT15
Recent independent agnostic pharmacogenomic studies have identified a novel pharmacogene important for 
thiopurines: the nudix hydrolase 15 gene (NUDT15, also known as MTH2), is ~10 kb long, and is located on 
q region of chromosome 13[38]. NUDT15 (EC 3.6.1.9) is an ubiquitously expressed nucleotide triphosphate 
diphosphatase that converts oxidized GTP to its monophosphate form, preventing the integration of the 
damaged purine nucleotides into DNA and subsequent mismatch repair[39]. The triphosphate thionucleotides 
are potential substrate for NUDT15 that can hydrolyse and inactivate them. In patients with defective 
NUDT15, treatment with a standard dose of MP leads to an excessive accumulation of tGTP/tdGTP and 
consequent extensive DNA damage and cytotoxicity[40].
Yang et al.[38] performed an Immunochip-based association study in 978 Korean CD patients treated 
with thiopurines, investigating the association of 196524 genetic variants previously shown to be genetic 
susceptibility loci for drug-induced leukopenia in autoimmune or inflammatory diseases. The missense 
SNP 415C>T of NUDT15 gene (rs116855232), that induces p.Arg139Cys change, was associated with early 
leukopenia in the combined analysis of the discovery and replication samples (OR = 35.6; P combined = 
4.88 × 10-94). Similarly, a GWAS study was conducted, using the HumanExomeBeadChip array (244770 
SNPs), on a discovery cohort including 657 ALL children and a replication cohort of 371 ALL patients. 
The association with MP dose intensity (defined as the ratio between clinician-prescribed MP dose and 
protocol dose) was investigated, finding rs1142345 in TPMT and rs116855232 in NUDT15 as significantly 
associated loci (P ~9 × 10-9) with independent replication. Patients that presented a homozygous TT 
genotype for NUDT15 rs116855232 were very sensitive to MP and they could tolerate only 8.3% of the 
usual MP dose; this polymorphism explains 22% of variance in thiopurine-tolerance[41]. Moriyama et al.[42] 
reported that NUDT15 variant p.Arg139Cys did not affect enzymatic activity but rather protein stability, 
likely due to a loss of supportive intramolecular bonds that caused rapid proteasomal degradation in cells. 
Moriyama et al.[47] sequenced all exons of NUDT15 in 3 ALL cohorts including 270 children from Guatemala, 
Singapore and Japan and identified 4 coding SNPs located in exons 1 and 3 associated with a loss of 
enzymatic activity (from 74.4% to 100%): the missense SNP rs116855232, the 416G>A SNP (rs147390019) that 
induces p.Arg139His and two other variants that affect the Val18 residue, the 52G>A resulting in a conversion 
of valine into isoleucine (p.Val18Ile) and the 36_37insGGAGTC insertion that leads to an in frame addition 
of a glycine and a valine residue (p.Val18_Val19insGlyVal). They also identified 5 NUDT15 haplotypes (*1-*5) 
with distinct combinations of these 4 variants and they classified patients into 3 diplotypic groups: normal 
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activity (*1/*1), intermediate activity (*1/*2, *1/*3, *1/*4 and *1/*5), and low activity (*2/*3, *3/*3 and *3/*5). 
Loss-of-function NUDT15 diplotypes were consistently associated with thiopurine intolerance. In vitro 
studies on human lymphoid cell line showed an increased level of active TGTP in the NUDT15 knock-down 
cells compared to control cells, with the elevation of intracellular incorporated DNA thionucleotides and 
consequently higher thiopurines induced apoptosis[42].
A meta-analysis study of NUDT15 variants investigating 1,752 patients from 7 independent cohorts (both 
ALL and IBD) showed a significant association between NUDT15 rs116855232 T allele and myelotoxicity: 
indeed, the presence of the T allele increases ~8 times the probability to have leukopenia in comparison 
to the C allele (P < 0.00001, OR = 7.86, 95% CI: 6.13, 10.08). Analysing 2745 patients from 13 cohorts, the 
authors also found that T carriers tolerated lower mean daily thiopurines dose (P < 0.00001)[43]. A second 
meta-analysis, including 16 studies on rs116855232 (p.Arg139Cys), confirmed its role as clinically relevant 
predictor of thiopurine-induced leukopenia[44]. This SNP is the most common NUDT15 genetic variant, 
particularly frequent in East Asians (10.4%) and Hispanics (7.1%), but almost absent in Europeans (0.46%) 
and Africans[45]. Distribution of other NUDT15 genetic variants are also ethnic specific: rs147390019 is 
common only in Hispanics (1.7%)[43] and rs186364861 in Asians (1.6%)[43]. Recently, a NUDT15 variant with 
a significant prevalence in Caucasian patients was discovered in a cohort of patients with IBD, rs746071566, 
(p.Gly17_Val18del) and was associated with myelosuppression during thiopurine therapy[46]. The relevance of 
this variant in Caucasian patients with ALL has still to be fully understood. 
International guidelines of thiopurines treatment suggest to consider NUDT15 together with TPMT 
genotypes before drug administration. Patients who present the above-mentioned genetic variants need to 
adjust drug dosage. CPIC suggests to use the normal starting dose for NUDT15 normal metabolizers (e.g., 
NUDT15 *1/*1, MP 75 mg/m2/day in ALL) and a reduced one in intermediate metabolizers (e.g., NUDT15 
*1/*3, MP 30%-80% normal starting dose) and poor metabolizers (e.g., NUDT15 *3/*3; MP 10 mg/m2/day in 
ALL)[36].
Moriyama et al.[47] evaluated the effects of NUDT15 on thiopurines metabolism and identified DNA-
incorporated thioguanine (DNA-TG) and TGN as pharmacologic markers for NUDT15 genotype-guided 
thiopurines dosing. They analyzed the level of these metabolites in a cohort of 55 Japanese ALL pediatric 
patients: those with NUDT15 deficiencies accumulated DNA-TG more efficiently than patients without 
NUDT15 variants (P = 4.0 × 10-9). They also showed that cytosolic TGN and nuclear DNA-TG were positively 
correlated with each other (P = 6.5 × 10-4), but the ratio of DNA-TG to TGN was significantly higher in 
NUDT15 deficient patients (P = 3.6 × 10-9), suggesting that DNA-TG is a more relevant MP metabolite than 
TGN to inform NUDT15 genotype-guided dose adjustments[47].
ITPA
Human inosine triphosphate pyrophosphatase (ITPA, EC 3.6.1.19) is a ~21 kDa enzyme that is ubiquitously 
expressed in the cytoplasm of cells and acts in homodimer form[48]. ITPA catalyses the hydrolysis of the 
triphosphate moieties from noncanonical (deoxy-) purine triphosphate, such as inosine triphosphate, deoxy-
inosine triphosphate, xanthosine triphosphate, deoxy-xantosine triphosphate (ITP, dITP, XTP and dXTP 
respectively), thus recovering the monophosphate derivatives and releasing the pyrophosphate group. IMP/
dIMP are fundamental intermediates in purine metabolism and can be converted into canonical adenosine 
monophosphate (AMP/dAMP, and therefore ATP/dATP) and guanosine monophosphate (GMP/dGMP, 
hence GTP/dGTP). It has been estimated that nearly one third of the human population has a genetically 
determined decreased ITPase activity[49]. The resulting unusual accumulation of noncanonical purine 
triphosphate can be toxic for the cells because of their interference with polymerase enzymes, and their 
incorporation into DNA or RNA. The 19 kb ITPA gene is located on the short arm of chromosome 20 and 
includes 8 exons[50]. Genetic knock-out (Itpa-/-) mice present abnormal features of growth retardation and 
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cardiac myofiber disarray and die within 2 weeks after birth, likely because of the accumulation of ITP 
in the nucleotide pool found in erythrocytes[51]. Some reports have associated ITPA variants to human 
diseases, such as psychiatric disorders, encephalopathy, young-onset tuberculosis and infertility[49,52-54]. The 
human ITPA gene carries several polymorphisms associated with a reduction of enzymatic activity among 
which ITPA SNPs rs1127354 and rs7270101. SNP rs1127354 consists in the C94A transversion at the exon 2 
level, leading to the amino acid substitution p.Pro32Thr. This substitution determines complete depletion of 
ITPA activity in homozygous individuals and a reduction to about 25% in heterozygous individuals[55]. The 
frequency of this polymorphism is around 5%-7% in the Caucasian population, but varies greatly depending 
on the ethnicity ranging from 2% in Hispanic populations up to 19% in Asians[56]. rs7270101 instead is the 
intronic transversion IVS2 +21A>C, that alters a very conserved adenine at the level of a splicing site, thus 
leading to an aberrant mRNA. This variant has a less severe effect than the C94A alteration: indeed, patients 
heterozygous for this SNP show an activity of about 60% compared to wild-type[55]. Genetic variants in 
ITPA are of major interest in pharmacogenetic research being associated with altered outcomes for patients 
undergoing antimetabolite therapy, in particular antileukemic agents such as thiopurines and methotrexate 
or antivirals such ribavirin or zidovudine[57,58]. 
The occurrence of toxicities during the ALL maintenance therapy was previously associated with ITPA 
variants: in the context of the SJCRH Total XIIIB protocol, Stocco et al.[59] found that ALL patients 
with a variant ITPA allele had a higher probability of developing severe febrile neutropenia. Increased 
accumulation of MMPN nucleotides has been described both in patients’ blasts, during a mercaptopurine-
based window therapy, and erythrocytes, during maintenance therapy with MP doses adjusted for TPMT 
genotype. Adam de Beaumais et al.[6] found that wild-type TPMT/variant ITPA ALL patients treated with 
the EORTC (European Organization for Research and Treatment of Cancer)-58951 protocol had higher 
MMPN concentration in erythrocytes in comparison to wild-type TPMT/wild-type ITPA and that a MMPN 
threshold above 5000 pmol/8 × 108 RBC was associated to an increased risk of hepatotoxicity. Controversial 
results were reported in Asian populations: Kim et al.[60] did not find a difference in the cumulative incidence 
of grade III/IV febrile neutropenia according to ITPA genotypes in Korean ALL pediatric patients whereas 
Malaysian patients with ITPA 94A allele seemed more prone to develop fever and liver toxicity in therapeutic 
protocols not individualized for TPMT[61]. An Italian pharmacogenetic multicentric study was performed 
on 508 pediatric ALL patients treated with the AIEOP-BFM 2000 protocol: four children were homozygous 
variant for rs1127354 (94 AA genotype) and had a significant 13-fold increase in the risk of developing severe 
(grade III-IV) neurological toxicities during the 2 months induction phase, when compared with wild-
type subjects, and showed also an higher risk of developing severe gastrointestinal complications (8-fold 
increase in risk)[62]. However, in this study, MP were introduced only four weeks after the beginning of the 
treatment, thus the incidence of these adverse effects could not be uniquely ascribable to thiopurines and the 
contribution of other drugs, such methotrexate, could be considered.
PACSIN2
Protein kinase C and casein kinase substrate in neurons protein 2 (PACSIN2) is a member of the PACSIN 
protein family[63]. PACSIN2 is an ubiquitously expressed protein of ~56 kDa and is localized in physical 
proximity to membranes. Structurally, PACSIN2 contains a membrane-sculpting Bin-Amphiphysin-Rvs 
(BAR) domain at N-terminal, a central region with a proline rich motif and a C-terminal Src homology 
3 (SH3) domain[64-65]. The F-BAR domain regulates membrane curvatures and invaginations formation 
involved in vesicle budding, endocytosis and caveole biogenesis[66-68], whereas the SH3 domain mediates 
the interaction with many membrane proteins. PACSIN2 is encoded by a 180kbp gene located in the long 
arm of chromosome 22 which includes 15 exons. Human and murine PACSIN2 cDNA and protein show 
significant homology with 79.8% and 93.6% identity, respectively. The PACSIN2 knock-out mouse presents 
a decreased mean corpuscular volume, decreased mean corpuscular hemoglobin concentration, decreased 
leukocyte cell number, increased heart weight and improved glucose tolerance[69]. A recent genome wide 
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analysis on a panel of 30 human HapMap cell lines trios demonstrated that the intronic SNP rs2413739 
(T>C) of PACSIN2 can influence TPMT activity. In ALL patients enrolled in the Total XIIIB/XV protocols 
at SJCRH, the TT genotype was associated with lower TPMT activity in patients’ RBC and with an higher 
rate of gastrointestinal toxicity during thiopurines therapy. This latter association was also validated in an 
independent cohort of ALL patients treated with the AIEOP-BFM ALL 2000 protocol[70]. A retrospective 
study in pediatric ALL patients treated with thiopurines suggested that the presence of rs2413739 in 
PACSIN2 gene is a significant risk factor for mercaptopurine induced hematological toxicity in patients with 
wild-type TPMT[71]. It could be hypothesized that the increased toxicities observed in rs2413739 TT carriers 
are due to lower TPMT activity. However, no contribution of rs2413739 on thiopurine metabolites (TGN and 
MMPN) was reported, thus the mechanistic link between the PACSIN2 SNP and thiopurine adverse effects 
is not yet clearly established. 
The PACSIN2 SH3 domain can interact with other proteins, such as Ras-related C3 botulinum toxin 
substrate 1 (Rac-1)[67]. Several evidences suggest a possible interplay among PACSIN2, Rac-1 and thiopurines. 
The physical interaction between the proline-rich hypervariable region of Rac-1 and the SH3 domain of 
PACSIN2 is well known. Due to its role in intracellular vesicle-mediated transport, PACSIN2 could serve as 
a molecular brake on Rac-1 signaling, by mediating the Rac-1-GTP internalization toward early endosomes, 
thus slowing down cell processes, such as growth and differentiation, regulated by the small GTPase[72]. The 
thiopurine metabolite tGTP binds to Rac-1 as a competitive antagonist of GTP: this binding suppresses the 
activation of Rac-1 and leads to apoptosis. Indeed, in IBD patients, effective MP therapy led to decreasing 
concentrations of Rac-1-GTP and Rac-1 expression[73]. PACSIN2 moreover may affect TPMT activity: indeed, 
the knock-down of PACSIN2 mRNA in human leukemia cells NALM6 resulted in significantly lower 
TPMT expression and enzymatic activity[70] that can in turn result in a higher tGTP availability and Rac-
1 inhibition. Although not clear enough, these evidences suggest that PACSIN2, Rac-1 and their expression 
level could be additional potential biomarkers of thiopurines response and should be further investigated.
Rac-1 
Rac proteins play a major role in T cell development, differentiation, and proliferation[74] and Rac-1 knock-
outs are embryonic lethal in mice[75]. Rho GTPase proteins cycle between a GDP-bound and a GTP-bound 
state through the action of guanine nucleotide exchange factors (GEFs) and the opposing GTPase activating 
proteins (GAP); the GTP-bound state is generally considered as the active conformation, regulating signaling 
pathways in cells. The binding of tGTP instead of GTP on Rac-1 suppresses its activation, and thus the 
activation of its downstream targets such as mitogen-activated protein kinase, NF-κB and the antiapoptotic 
protein Bcl-xL. In vivo and in vitro studies suggested that Rac-1 plays a key role in thiopurines mechanism 
of action[24]. Tiede and collaborators have demonstrated that binding of AZA-generated tGTP to Rac-1 
induced the mitochondrial pathway of apoptosis in primary CD4+ T lymphocytes lamina propria cells of 
healthy volunteers and CD patients, by downregulating Bcl-xL mRNA and protein[24]. An in vitro study 
on primary T cells isolated from healthy donors clarified the molecular mechanism beneath the tGTP-
block of Rac-1, showing that the accumulation of inactive tGDP-Rac-1 proteins over time depends on the 
inhibition of the GEF factor Vav[76]. IBD patients treated with these drugs present a reduced median Rac-
1 expression compared with patients without immunosuppressive therapy, and among MP treated patients, 
non-responders showed an increased median active Rac-1 expression[73]. In animal models, neutrophil and 
macrophage conditional Rac1 knock-out show normal bowel histology and do not present any obvious 
colonic phenotype; nonetheless they are protected against dextran sulphate sodium-induced colitis and 
show a reduced level of the proinflammatory cytokine IL-1β and of the neutrophil chemokine KC compared 
to wild-type mice[77]. The pharmacogenetics of RAC1, a ~30 kDa gene located on p arm of chromosome 7, 
has been investigated in IBD, but not in ALL patients. Two intronic RAC1 polymorphisms (rs10951982 and 
rs4720672) have been associated with UC susceptibility in a discovery and in 2 independent replication 
cohorts; IBD patients who had the rs10951982 G risk allele had increased expression of RAC1 compared 
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to those without this allele[77]. The same SNPs, together with RAC1 SNP rs34932801, was genotyped in 
59 IBD pediatric patients and no association was found with thiopurine effectiveness after 12 months of 
therapy[78]. In contrast, a retrospective report on a cohort of 156 thiopurine-treated CD adults has shown an 
association between the GC heterozygous genotype in SNP rs34932801 and poorer response to thiopurines, 
in comparison to wild-type GG[79].
Epigenetics
Epigenetic factors, in particular considering molecular factors that can be inherited from one generation 
to the other but that do not depend on the DNA sequence, such as methylation of cytosines on DNA and 
non-coding RNA profiles, such as microRNAs (miRNAs) and long non-coding RNAs, have been recently 
considered as innovative pharmacogenomic determinants of interindividual variability in drug efficacy and 
toxicity[80].
For thiopurines, studies on the effect of pharmacoepigenetic factors are still limited. Thiopurines have been 
shown to reduce global DNA methylation[81]. This effect was demonstrated in vitro in human leukemia 
cells and has been related to the reduction of de novo purine synthesis (DNPS) induced by thionucleotides, 
which determines reduction in ATP levels and depletion of S-adenosylmethionine (SAM) concentration, 
an important co-factor of methyltransferases, including DNA methyltransferases, enzymes involved in the 
regulation of DNA methylation[82]. Also TPMT activity, by modulating the capability of thionucleotides to 
inhibit DNPS, has been shown to influence the reduction of DNA methylation induced by mercaptopurine 
and thioguanine[83]. However, how this effect of thiopurines on DNA methylation may be related to 
interindividual variability in efficacy and adverse effects of these drugs or on the expression of candidate 
genes involved in thiopurines pharmacokinetics and pharmacodynamics is still unknown. 
In the treatment of pediatric ALL, mercaptopurine is generally associated with methotrexate, both during 
consolidation and maintenance therapies. The epigenetic factors influencing interindividual variability in 
response to these phases of therapy may be of relevance also for thiopurine effects. For examples, a major 
adverse effect of consolidation therapy for pediatric ALL is oral mucositis, which is generally ascribed to 
methotrexate. However, as already mentioned, in some protocols, such as SJCRH Total XIIIB protocol, 
this adverse effect has been related also to TPMT activity[70], which indicated that also interindividual 
variability in mercaptopurine disposition may influence this adverse effect. A recent study evaluated DNA 
methylation profiles associated with oral mucositis during consolidation therapy in children with ALL. This 
study confirmed also in patients a significant reduction in SAM levels during methotrexate/mercaptopurine 
therapy (doses respectively 5 g/m2 every 2 weeks with leucovorin rescue 15 mg/m2/dose and daily 
mercaptopurine 25 mg/m2). In this study, DNA methylation was measured considering the percentage of 12 
CpG islands in the LINE1 gene, that is considered a surrogate for DNA global methylation[84]. Intriguingly, 
a small increase in this DNA methylation marker was observed during therapy, with no correlation with 
SAM levels and incidence of oral mucositis. One limitation of this study is that DNA was extracted from 
peripheral blood mononuclear cells and since DNA methylation is cell specific, different effects could 
be observed in tissues more directly involved in methotrexate/mercaptopurine, effects such as residual 
lymphoblasts and epithelial cells of the gastrointestinal tract.
Considering non coding RNAs, studies are also limited, in particular for the association with the clinical 
effects of thiopurines. One study considered miRNA profiles after treatment with mercaptopurine in rat 
placenta, as a model to study toxicity of this drug in fetal development. Differentially expressed miRNAs 
could be identified and were involved in process such as apoptosis, inflammation and ischemia[85]. 
Non coding RNAs affecting the expression of pharmacogenes in human liver have been identified and 
associated with age. Among these genes, also those relevant for thiopurines pharmacokinetics have been 
considered[86]. Results showed that some miRNAs were associated with both age and TPMT expression; in 
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particular, hsa-miR-34a-5p and has-miR-125b-5p showed the largest significant negative correlation with 
TPMT expression. Interestingly, TPMT activity measured in erythrocytes is negatively associated with age 
in children with ALL[23] and age has been shown to modulate thiopurine pharmacokinetics in pediatric 
patients[87]. The molecular mechanisms by which age influences TPMT activity could involve epigenetic 
factors, however more research is needed to clarify this phenomenon.
While the contribution of epigenetic factors to mercaptopurine induced adverse effects in pediatric ALL is 
still uncertain and speculative, further studies on this topic may bring important insights to improve therapy 
of patients taking mercaptopurine.
Genotyping vs. phenotyping
Many genes involved in thiopurine pharmacogenetics (i.e., TPMT, NUDT15, ITPA) encode for enzymes 
whose activity can be measured in patients, for examples in erythrocytes. For TPMT there are many studies 
considering both phenotyping and genotyping, while for the other enzymes the information available is still 
limited. 
Both TPMT genotyping or phenotyping before starting thiopurines treatment allows to identify patients with 
reduced enzymatic activity and increased risk of drug induced adverse effects and to adjust starting dose 
accordingly or to use an alternative therapy. There is a risk of TPMT misclassification when only genotyping 
or phenotyping is used. Genotype-phenotype concordances are usually set between 76% and 99%[22]. Indeed, 
the conduction of both tests may give clinicians a more complete picture about patient’s risks during therapy, 
but there is no consensus on the evaluation of both in all patients, also for the associated costs. The Food and 
Drug Administration (FDA) still indicates genotyping or phenotyping before drug administration to identify 
TPMT status[88], while the American College of Gastroenterology indicates phenotyping as the first choice 
for patients using thiopurines for IBD because phenotyping reports a quantitative level of TPMT enzyme 
activity[89]. Genotyping certainly detects variations useful to predict the enzyme activity and the possible 
development of adverse effects directly associated with enzyme deficiency. One advantage of genetic tests is 
that they can be performed before starting therapy and the information obtained will be unchanged for the 
entire patient lifespan. Despite the relatively simple and rapid procedure, genetic tests provide data about 
key variants generally detecting the most common genetic variants associated with enzyme decrease but is 
not able to give a full prediction because they do not verify the presence of rare or previously undiscovered 
variants that will not be detected by variant-specific genotyping methods[90]. The advent of genome wide and 
next-generation sequencing (NGS) approaches and the continued reduction in the costs of these technologies 
will partly overcome this problem. Moreover, the genotype is not solely responsible for patient’s susceptibility 
of a drug. Genotyping tests will always provide a partial point of view since they do not consider variability 
of enzyme activity due to the presence of drug interactions, presence of others pathologies or other 
epigenetic factors. Phenotyping consists in a more direct observation of how the drug is metabolized and 
considers also inter-individual differences between patients with the same genetic arrangement. For this 
purpose, the activity of TPMT in lysed erythrocytes can be directly and successfully determined using 
reversed-phase high performance liquid chromatography (HPLC)[91]. It is important to measure TPMT 
activity on a blood sample taken before starting thiopurine administration and during therapy, because its 
activity can increase during treatment and thus can interfere with test results[36]. Moreover, phenotyping test 
shall be performed at least 3 months after a transfusion of erythrocytes[92]: during ALL chemotherapy many 
patients receive transfusions therefore the utility of phenotyping in this setting may be limited.
In conclusion, TPMT genotyping and phenotyping provide complementary information. Despite the usually 
quite high levels of concordance between the analysis, the combination of both genotype and phenotype 
tests insures a higher precision in the treatment personalization. 
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CONCLUSION
With the development of highly efficient sequencing techniques and the expected more diffuse availability 
of patient specific genotyping data, particularly for severe life threatening disease such as pediatric ALL, 
thiopurines pharmacogenetics may significantly contribute to reduce adverse effects and improve efficacy, 
by considering multilocus genotyping of TPMT and NUDT15. More research is needed to further improve 
pharmacogenetics of thiopurines by including additional gene variants, such as ITPA and PACSIN2, to 
obtain further clinical and mechanistic evidence. 
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